ConductScience.org, home

Paper · 36976456

Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.

Sangro P and 3 others. J Physiol Biochem, 2023. Cited by 119 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. Papers, record 36976456. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36976456

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment.
PubMed
Journal
J Physiol Biochem
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
119
iCite
Relative citation ratio, by iCite
14.6
iCite
Revised in PubMed
2023-11-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sangro PPalomahttps://orcid.org/0000-0001-9753-9667
2de la Torre Aláez MManuelhttps://orcid.org/0000-0002-1972-3933
3Sangro BBrunohttps://orcid.org/0000-0002-4177-6417
4D'Avola DDeliahttps://orcid.org/0000-0002-0907-6648

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Non-alcoholic Fatty Liver DiseaseMajor topic
Humans
Disease Progression
Inflammation
Liver Cirrhosis

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References65

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121,848,324When galectins recognize glycans: from biochemistry to physiology and back again.Biochemistry2011https://conductscience.org/library/papers/21848324PubMed
224,222,941PNPLA3 I148M polymorphism and progressive liver disease.World J Gastroenterol2013https://conductscience.org/library/papers/24222941PubMed
330,067,154Mechanisms of Insulin Action and Insulin Resistance.Physiol Rev2018https://conductscience.org/library/papers/30067154PubMed
421,295,846National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants.Lancet2011https://conductscience.org/library/papers/21295846PubMed
520,176,643Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease.Gut2010https://conductscience.org/library/papers/20176643PubMed
615,146,238Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.J Clin Invest2004https://conductscience.org/library/papers/15146238PubMed
719,359,429Inflammasome-mediated regulation of hepatic stellate cells.Am J Physiol Gastrointest Liver Physiol2009https://conductscience.org/library/papers/19359429PubMed
831,731,005
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Contemp Clin Trials2020https://conductscience.org/library/papers/31731005PubMed
916,890,538Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis.Cell Metab2006https://conductscience.org/library/papers/16890538PubMed
1029,159,325Role of Aramchol in steatohepatitis and fibrosis in mice.Hepatol Commun2017https://conductscience.org/library/papers/29159325PubMed

Cited by78

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 119 citations.

PMIDTitleJournalYearIn PapersSource
42,579,267Short-Term Impact of Endoscopic Gastric Remodeling in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.Obes Surg2026https://conductscience.org/library/papers/42579267PubMed
42,534,806Plant metabolites targeting the AMPK pathway: advances in the mechanisms of action in the context of MAFLD.Front Pharmacol2026https://conductscience.org/library/papers/42534806PubMed
42,487,340Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis.J Gastroenterol Hepatol2026https://conductscience.org/library/papers/42487340PubMed
42,446,679Unrevealing the Role of Flavonoids in Mitigation of Non-Alcoholic Fatty Liver Disease.Med Chem Res2026https://conductscience.org/library/papers/42446679PubMed
42,212,530Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine-to-Caffeine Metabolic Ratio: A Pharmacokinetic Study.J Clin Pharmacol2026https://conductscience.org/library/papers/42212530PubMed
42,121,292Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42121292PubMed
42,075,864Effects of Chaenomeles japonica Fruit Juice on Energy Balance and Biochemical and Histological Parameters in a Model of Diet-Induced Metabolic Syndrome in Rats.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42075864PubMed
42,064,079Integrated bioinformatics and machine learning identify early diagnostic biomarkers for MAFLD with comorbid psoriasis.Front Immunol2026https://conductscience.org/library/papers/42064079PubMed
42,007,332Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.Front Pharmacol2025https://conductscience.org/library/papers/42007332PubMed
41,993,620Context-dependent Activities of Mitrephorone Link Lipid Redirection, Anti-inflammatory Action, and Ferroptosis Control to Hepatocyte Protection.Theranostics2026https://conductscience.org/library/papers/41993620PubMed

1 to 10 of 78

See all 78 cited by

Genes39

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36976456

GET https://conductscience.org/api/papers/v1/36976456/references?page=2